A recent meta-analysis study on the expression of PD-L1 has shown that patients with RCC harboring high expression of PD-L1 in tumors responded significantly better to both PD-1 and PD-L1 antibody therapies compared to patients with low or negative PD-L1 expression in tumor cells (221). Here, CD274 is linked to renal cell adenocarcinoma.